Total
0
Shares
Orthocell (ASX:OCC) - CEO, Paul Anderson (left)
CEO, Paul Anderson (left)
Source: Orthocell
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Orthocell (OCC) appoints Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia
  • Headquartered in Sydney, SMT provides innovative and clinically proven medical and cosmetic technologies across Australia and New Zealand
  • Striate+ is a dental collagen membrane used for bone and tissue regeneration procedures, and consists of both a smooth and rough side
  • The smooth side prevents gingival soft tissue growing during bone healing while the rough side helps new bone growth
  • Orthocell is up 3.60 per cent with shares trading at 57.5 cents at 12:20 pm AEST

Orthocell (OCC) has appointed Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia.

Headquartered in Sydney, Samson Medical Technologies provides innovative and clinically proven medical and cosmetic technologies across Australia and New Zealand.

It has established relationships with leading plastic, reconstructive, oral and maxillofacial surgeons across Australia.

SMT will now distribute Striate+ for use in bone and soft tissue repairs. It will also undertake targeted promotion activities and initiate sales.

Founder and CEO of SMT Andrew Nutman is excited to begin working with Orthocell and distribute Striate+ across a wide range of industries.

“I am extremely excited to be working with Orthocell to distribute its Australian-made range of dental and maxillofacial collagen membranes in Australia,” Mr Nutman said.

“We look forward to working with the team at Orthocell to make Striate+ (CelGro Dental) the product of choice amongst the oral surgical and dental implant industry.”

Striate+ is a dental collagen membrane used for bone and tissue regeneration procedures. it consists of both a smooth and rough side.

The smooth side is placed facing the oral cavity to prevent gingival soft tissue growing during bone healing while the rough side is placed facing the defect to help new bone growth.

Orthocell Managing Director Paul Anderson is pleased to be working with an experienced and highly regarded company such as SMT.

“SMT is a leading distributor of innovative medical devices with an experienced team to assist in managing the market entry, promotion of distribution of Striate+,” Mr Anderson said.

“SMT is the ideal partner in our local market with established relationships with oral surgeons and a successful track record of driving market entry of high quality products.”

Orthocell was up 3.60 per cent with shares trading at 57.5 cents at 12:20 pm AEST.

OCC by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Executive Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) shuffles board

Rhythm Biosciences (RHY) has restructured its board and management team, effective immediately.

" Epsilon Healthcare (ASX:EPN) extends agreement with The Valens Company

Epsilon Healthcare (EPN) has extended its agreement with The Valens Company to January 31, 2022.
Starpharma (ASX:SPL)

" Starpharma’s (ASX:SPL) nasal spray registered for sale in Vietnam

Starpharma’s (SPL) VIRALEZE product has been registered for sale in Vietnam.  
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals’ (ASX:TLX) Illuccix authorised in Brazil

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.